EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis

Annika Glotzbach,Katharina Rohlf,Anastasia Gonscharow,Simon Lüke,Özlem Demirci,Brigitte Begher-Tibbe,Nina Overbeck,Jörg Reinders,Cristina Cadenas,Jan G. Hengstler,Karolina Edlund,Rosemarie Marchan
DOI: https://doi.org/10.1186/s13058-024-01849-y
2024-06-01
Breast Cancer Research
Abstract:Despite progress understanding the mechanisms underlying tumor spread, metastasis remains a clinical challenge. We identified the choline-producing glycerophosphodiesterase, EDI3 and reported its association with metastasis-free survival in endometrial cancer. We also observed that silencing EDI3 slowed cell migration and other cancer-relevant phenotypes in vitro. Recent work demonstrated high EDI3 expression in ER-HER2+ breast cancer compared to the other molecular subtypes. Silencing EDI3 in ER-HER2+ cells significantly reduced cell survival in vitro and decreased tumor growth in vivo. However, a role for EDI3 in tumor metastasis in this breast cancer subtype was not explored. Therefore, in the present work we investigate whether silencing EDI3 in ER-HER2+ breast cancer cell lines alters phenotypes linked to metastasis in vitro, and metastasis formation in vivo using mouse models of experimental metastasis.
oncology
What problem does this paper attempt to address?